Mind Medicine (MindMed) (MNMD) Competitors $6.59 +0.20 (+3.13%) Closing price 04:00 PM EasternExtended Trading$6.56 -0.04 (-0.53%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock MNMD vs. ARWR, AAPG, HRMY, GLPG, CNTA, ARQT, IDYA, AGIO, CGON, and ANIPShould you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Arrowhead Pharmaceuticals (ARWR), Ascentage Pharma Group International (AAPG), Harmony Biosciences (HRMY), Galapagos (GLPG), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Mind Medicine (MindMed) vs. Arrowhead Pharmaceuticals Ascentage Pharma Group International Harmony Biosciences Galapagos Centessa Pharmaceuticals Arcutis Biotherapeutics IDEAYA Biosciences Agios Pharmaceuticals CG Oncology ANI Pharmaceuticals Mind Medicine (MindMed) (NASDAQ:MNMD) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment. Does the media favor MNMD or ARWR? In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 10 mentions for Arrowhead Pharmaceuticals and 2 mentions for Mind Medicine (MindMed). Arrowhead Pharmaceuticals' average media sentiment score of 1.55 beat Mind Medicine (MindMed)'s score of 0.94 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mind Medicine (MindMed) 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is MNMD or ARWR more profitable? Mind Medicine (MindMed)'s return on equity of -47.56% beat Arrowhead Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mind Medicine (MindMed)N/A -47.56% -35.55% Arrowhead Pharmaceuticals N/A -236.60%-64.09% Which has better earnings and valuation, MNMD or ARWR? Mind Medicine (MindMed) has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMind Medicine (MindMed)N/AN/A-$95.73M-$2.08-3.16Arrowhead Pharmaceuticals$2.50M776.77-$599.49M-$5.17-2.74 Which has more risk & volatility, MNMD or ARWR? Mind Medicine (MindMed) has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Do analysts prefer MNMD or ARWR? Mind Medicine (MindMed) currently has a consensus target price of $25.11, indicating a potential upside of 282.50%. Arrowhead Pharmaceuticals has a consensus target price of $41.44, indicating a potential upside of 193.06%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, research analysts plainly believe Mind Medicine (MindMed) is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.23Arrowhead Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do institutionals & insiders have more ownership in MNMD or ARWR? 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor MNMD or ARWR? Arrowhead Pharmaceuticals received 494 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 93.22% of users gave Mind Medicine (MindMed) an outperform vote while only 65.51% of users gave Arrowhead Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMind Medicine (MindMed)Outperform Votes5593.22% Underperform Votes46.78%Arrowhead PharmaceuticalsOutperform Votes54965.51% Underperform Votes28934.49% SummaryMind Medicine (MindMed) beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Mind Medicine (MindMed) News Delivered to You Automatically Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNMD vs. The Competition Export to ExcelMetricMind Medicine (MindMed)Medicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$494.04M$1.23B$5.49B$7.94BDividend YieldN/AN/A5.11%4.23%P/E Ratio-2.9010.9922.5818.55Price / SalesN/A10.22397.25103.00Price / CashN/A10.4038.1834.62Price / Book3.461.456.704.26Net Income-$95.73M-$56.07M$3.23B$248.39M7 Day Performance2.10%3.91%1.26%1.27%1 Month Performance18.50%23.68%3.75%3.85%1 Year Performance-30.38%-37.40%15.78%5.23% Mind Medicine (MindMed) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNMDMind Medicine (MindMed)2.3093 of 5 stars$6.59+3.1%$25.11+281.0%-32.9%$496.68MN/A-2.9240Upcoming EarningsARWRArrowhead Pharmaceuticals3.6149 of 5 stars$12.07+7.4%$41.44+243.4%-38.6%$1.66B$2.50M-2.33400Upcoming EarningsNews CoveragePositive NewsAAPGAscentage Pharma Group InternationalN/A$18.87+0.8%N/AN/A$1.64B$980.65M0.00600HRMYHarmony Biosciences4.8256 of 5 stars$28.50+0.1%$53.33+87.1%-4.7%$1.63B$714.73M13.51200Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsGLPGGalapagos0.617 of 5 stars$24.59-0.3%$25.33+3.0%-5.4%$1.62B$275.65M0.001,310Options VolumeCNTACentessa Pharmaceuticals2.5652 of 5 stars$12.11-1.5%$27.71+128.9%+49.7%$1.61B$6.85M-7.92200News CoveragePositive NewsARQTArcutis Biotherapeutics2.7594 of 5 stars$13.54+4.1%$18.80+38.8%+79.2%$1.61B$196.54M-7.56150Upcoming EarningsPositive NewsIDYAIDEAYA Biosciences3.7128 of 5 stars$18.23+6.7%$53.58+193.9%-50.5%$1.60B$7M-5.5280Upcoming EarningsPositive NewsAGIOAgios Pharmaceuticals4.2327 of 5 stars$27.43-0.8%$56.57+106.2%-8.6%$1.57B$36.50M2.42390Earnings ReportAnalyst RevisionNews CoverageCGONCG Oncology2.1113 of 5 stars$20.37-1.3%$59.33+191.3%-33.0%$1.55B$1.14M-14.3561Upcoming EarningsAnalyst ForecastNews CoverageANIPANI Pharmaceuticals4.4453 of 5 stars$68.16-1.5%$80.13+17.6%+7.3%$1.48B$614.38M-123.93600Positive News Related Companies and Tools Related Companies ARWR Alternatives AAPG Alternatives HRMY Alternatives GLPG Alternatives CNTA Alternatives ARQT Alternatives IDYA Alternatives AGIO Alternatives CGON Alternatives ANIP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNMD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
